About
Hunter Syndrome
Hunter syndrome is Mucopolysaccharidosis type II (MPS II). It takes its name from Charles Hunter (1873-1955) who first described two brothers with the disease in 1917.
MPS II is a rare X-linked lysosomal storage disorder caused by a deficiency of a specific enzyme, iduronate-2-sulfatase (IDS). In affected patients, glycosaminoglycan (GAG) accumulates in the lysosomes of many organs and tissues contributing to the pathology associated with MPS II.
Hunterase
Hunterase (Idursulfase-β) is indicated for patients with Hunter Syndrome (Mucopolysaccharidosis II, MPS II) as an enzyme replacement therapy (ERT).
Hunterase ICV
Hunterase ICV is indicated for patients with
Hunter Syndrome (Mucopolysaccharidosis II, MPS II) as an enzyme replacement therapy (ERT)
administered intracerebroventricularly (ICV).
Mechanism of Action
How to Use
Learn More
Diagnostic Algorithm
Learn More
Safety Information
Learn More
